MedTrace Logo

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

NCT03583021 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-05-29

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in male patients who are reversed with sugammadex or neostigmine.

Conditions

  • Gallbladder Diseases

Interventions

DRUG

Sugammadex Injectable Product

Sugammadex of 3 mg/kg is injected.

DRUG

Neostigmine Injectable Product

Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Ji Eun Kim · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2018-10-31
Completion
2018-12-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03583021 on ClinicalTrials.gov